| Followers | 23 |
| Posts | 14809 |
| Boards Moderated | 0 |
| Alias Born | 01/16/2026 |
Wednesday, February 04, 2026 4:47:18 PM
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
February 4, 2026 4:30 PM
Business Wire
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 4:00 p.m. ET.
A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations, and a replay will be available for up to 30 days following the event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260204548656/en/
Investors:
888-969-7879
IR@travere.com
Media:
888-969-7879
mediarelations@travere.com
Original: Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
Recent TVTX News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 02:36:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 08:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 01:49:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 01:48:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 01:48:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/16/2026 01:46:38 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:16:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:14:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 08:13:33 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 12:53:49 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 12:47:19 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/15/2026 12:40:33 AM
- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/14/2026 09:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/14/2026 08:20:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/14/2026 08:09:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/14/2026 08:02:56 PM
- Travere Shares Jump 44% After FDA Approval for Rare Kidney Disease Treatment • IH Market News • 04/14/2026 01:39:06 PM
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS • GlobeNewswire Inc. • 04/14/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/14/2026 12:11:31 AM
- Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS • Business Wire • 04/13/2026 10:16:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 10:17:22 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/06/2026 08:10:39 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/06/2026 08:09:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/06/2026 08:07:43 PM
